Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(16 years from now) | |
US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(18 years from now) |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases
Dosage: GRANULES;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(10 years from now) |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic